Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado

Background: Recent trials show that > 90% of patients with early stage Hodgkin`s Lymphoma (ESHL) can be cured, especially when using the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapeutic (CT) protocol. The use of radiotherapy (RT) is variable and can be selected accordi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Díaz,Javier, Soto,Katherine, Ernst,Daniel
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2017
Materias:	Chile Hodgkin Disease Lymphoma Positron Emission Tomography Computed Tomography
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000500009
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872017000500009
record_format	dspace
spelling	oai:scielo:S0034-988720170005000092017-11-16Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizadoDíaz,JavierSoto,KatherineErnst,Daniel Chile Hodgkin Disease Lymphoma Positron Emission Tomography Computed Tomography Background: Recent trials show that > 90% of patients with early stage Hodgkin`s Lymphoma (ESHL) can be cured, especially when using the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapeutic (CT) protocol. The use of radiotherapy (RT) is variable and can be selected according to the presence of specific risk factors, including PET-CT, as recently reported. Aim: To report the experience in the treatment of ESHL. Material and Methods: Retrospective and descriptive analysis of patients with ESHL treated at the Red de Salud UC-Christus between 2011-2015. Results: Twenty-two patients were treated. In 73%, the tumor was of nodular sclerosis histologic type. Most patients (95%) were in stage II, and 78% had a favorable prognosis according to the Deutsche Hodgkin Studiengruppe (GHSG) criteria. All patients were stratified using PET-CT and treated using the ABVD CT protocol, for 4-6 cycles. Only 5 patients received RT. There was no change of conduct after interim-PET-CT results. Ninety one percent of patients achieved complete response and there were two cases of refractory disease. Both cases underwent hematopoietic stem cell transplantation. After 17 months of median follow-up, 91% of patients are relapse-free, and only one patient died (5%). Conclusions: ABVD offers excellent results for ESHL patients. The benefit of PET-CT should be evaluated with prospective protocols, aiming to select patients needing RT or to reduce the number of CT cycles.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.145 n.5 20172017-05-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000500009es10.4067/S0034-98872017000500009
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Chile Hodgkin Disease Lymphoma Positron Emission Tomography Computed Tomography
spellingShingle	Chile Hodgkin Disease Lymphoma Positron Emission Tomography Computed Tomography Díaz,Javier Soto,Katherine Ernst,Daniel Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado
description	Background: Recent trials show that > 90% of patients with early stage Hodgkin`s Lymphoma (ESHL) can be cured, especially when using the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapeutic (CT) protocol. The use of radiotherapy (RT) is variable and can be selected according to the presence of specific risk factors, including PET-CT, as recently reported. Aim: To report the experience in the treatment of ESHL. Material and Methods: Retrospective and descriptive analysis of patients with ESHL treated at the Red de Salud UC-Christus between 2011-2015. Results: Twenty-two patients were treated. In 73%, the tumor was of nodular sclerosis histologic type. Most patients (95%) were in stage II, and 78% had a favorable prognosis according to the Deutsche Hodgkin Studiengruppe (GHSG) criteria. All patients were stratified using PET-CT and treated using the ABVD CT protocol, for 4-6 cycles. Only 5 patients received RT. There was no change of conduct after interim-PET-CT results. Ninety one percent of patients achieved complete response and there were two cases of refractory disease. Both cases underwent hematopoietic stem cell transplantation. After 17 months of median follow-up, 91% of patients are relapse-free, and only one patient died (5%). Conclusions: ABVD offers excellent results for ESHL patients. The benefit of PET-CT should be evaluated with prospective protocols, aiming to select patients needing RT or to reduce the number of CT cycles.
author	Díaz,Javier Soto,Katherine Ernst,Daniel
author_facet	Díaz,Javier Soto,Katherine Ernst,Daniel
author_sort	Díaz,Javier
title	Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado
title_short	Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado
title_full	Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado
title_fullStr	Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado
title_full_unstemmed	Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado
title_sort	excelente respuesta a tratamiento con abvd en pacientes con linfoma de hodgkin localizado
publisher	Sociedad Médica de Santiago
publishDate	2017
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000500009
work_keys_str_mv	AT diazjavier excelenterespuestaatratamientoconabvdenpacientesconlinfomadehodgkinlocalizado AT sotokatherine excelenterespuestaatratamientoconabvdenpacientesconlinfomadehodgkinlocalizado AT ernstdaniel excelenterespuestaatratamientoconabvdenpacientesconlinfomadehodgkinlocalizado
_version_	1718436944025747456

Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado

Ejemplares similares